Brand Name :
Mysoline
Synonyms :
primidone
Class :
Barbiturate anticonvulsants
Dosage Forms & Strengths
Tablet
50mg
250mg
Initially:
100 - 125
mg
Orally
at bedtime
3
days
then 100-125 mg twice a day for 3 days
following 100-125 mg thrice a day for 3 days, then 250 mg thrice to four times a day; without exceeding 2 g/day
Dose Adjustments
Dosing considerations:
Should not exceed more than 2 g/day
Do not stop abruptly, due to the chances of risk to status epilepticus
Therapeutic efficacy may take several weeks to achieve
Tablet
50mg
250mg
Refer to adult dosing
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may decrease the levels of serum concentration of maribavir
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of primidone
may diminish the serum concentration of primidone
may diminish the serum concentration of primidone
may enhance serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 Inducers
may increase the CNS depressant effect of primidone
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may decrease the serum concentration when combined with CYP3A4 Inducers (Strong)
may increase or decrease the activity of this enzyme when combined with sparsentan
may diminish the serum concentration when combined with alfentanil
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with aripiprazole
may diminish serum concentrations when combined with aripiprazole lauroxil
may diminish the serum concentration when combined with atogepant
may diminish the serum concentration when combined with belumosudil
may diminish the serum concentration when combined with brexpiprazole
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with fenfluramine
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
clopidogrel: they may enhance serum concentrations of CYP2C19 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
diltiazem: they may diminish the serum concentration of CYP3A4 Inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
CYP3A4 inducers: they may diminish the serum concentration of eravacycline
erlotinib: they may diminish the serum concentration of CYP3A4 inducers
etoposide: they may diminish the serum concentration of CYP3A4 inducers
exemestane: they may diminish the serum concentration of CYP3A4 Inducers
felodipine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 inducers: they may diminish the serum concentration of ganaxolone
may increase the CNS depressant effect of Buprenorphine
may diminish the serum concentration of zanubrutnib
drospirenone/ethinyl estradiol/levomefolate
may diminish the serum concentration of Hormonal Contraceptives
buprenorphine,long-acting injection
may increase the CNS depressant effect of Buprenorphine
it decreases the concentration of rilpivirine in the serum
primidone decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
may increase the levels of each other by decreasing the metabolism
may reduce the therapeutic effect of hemin
may reduce the level of serum concentration of abemaciclib
methyldopa/hydrochlorothiazide
may increase the hypotensive effect of blood pressure-lowering agents
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of primidone
may diminish serum concentrations of CYP3A4 inducers
may enhance the serum concentration when combined with CYP3A4 substrates
they decrease the concentration of glasdegib in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
may enhance the serum concentration when combined with CYP3A4 substrates